Product Name
GABRG2, siRNA
Full Product Name
GABRG2 siRNA (Rat)
Product Synonym Names
Gamma-aminobutyric acid receptor subunit gamma-2; GABA(A) receptor subunit gamma-2
Product Gene Name
GABRG2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P18508
Specificity
GABRG2 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat GABRG2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of GABRG2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
GABRG2 sirna
siRNA to inhibit GABRG2 expression using RNA interference
Applications Tested/Suitable for GABRG2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for GABRG2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_899156.1
[Other Products]
NCBI GenBank Nucleotide #
NM_183327.1
[Other Products]
UniProt Primary Accession #
P18508
[Other Products]
UniProt Related Accession #
P18508[Other Products]
Molecular Weight
54,077 Da
NCBI Official Full Name
gamma-aminobutyric acid receptor subunit gamma-2
NCBI Official Synonym Full Names
gamma-aminobutyric acid (GABA) A receptor, gamma 2
NCBI Official Symbol
Gabrg2 [Similar Products]
NCBI Protein Information
gamma-aminobutyric acid receptor subunit gamma-2
UniProt Protein Name
Gamma-aminobutyric acid receptor subunit gamma-2
UniProt Synonym Protein Names
GABA(A) receptor subunit gamma-2
Protein Family
Gamma-aminobutyric acid receptor
UniProt Gene Name
Gabrg2 [Similar Products]
UniProt Entry Name
GBRG2_RAT
NCBI Summary for GABRG2
subunit of GABA receptors, which bind benzodiazepines and act as inhibitory ion channels in the brain [RGD, Feb 2006]
UniProt Comments for GABRG2
GABRG2 iso2: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Defects in GABRG2 are the cause of childhood absence epilepsy type 2 (ECA2). ECA2 is a subtype of idiopathic generalized epilepsy (IGE) characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. During adolescence, tonic-clonic and myoclonic seizures develop. Some individuals manifest ECA2 occurring in combination with febrile convulsions. Defects in GABRG2 are the cause of familial febrile convulsions type 8 (FEB8). A febrile convulsion is defined as a seizure event in infancy or childhood, usually occurring between 6 months and 6 years of age, associated with fever but without any evidence of intracranial infection or defined pathologic or traumatic cause. Febrile convulsions affect 5-12% of infants and children up to 6 years of age. There is epidemiological evidence that febrile seizures are associated with subsequent afebrile and unprovoked seizures in 2% to 7% of patients. Defects in GABRG2 are the cause of generalized epilepsy with febrile seizures plus type 3 (GEFS+3). Generalized epilepsy with febrile seizures-plus refers to a rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. GEFS+ is a disease combining febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity. Defects in GABRG2 are a cause of severe myoclonic epilepsy in infancy (SMEI); also called Dravet syndrome. SMEI is a rare disorder characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development delay is observed around the second year of life. SMEI is considered to be the most severe phenotype within the spectrum of generalized epilepsies with febrile seizures-plus. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRG2 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Channel, chloride; Membrane protein, integral; Transporter, ion channel; Membrane protein, multi-pass; Channel, ligand-gated; Transporter
Cellular Component: postsynaptic membrane; integral to plasma membrane; axon; cytoplasm; cell junction
Molecular Function: protein binding; chloride channel activity; GABA-A receptor activity; GABA receptor activity; inhibitory extracellular ligand-gated ion channel activity
Biological Process: synaptic transmission; ***** behavior; synaptic transmission, GABAergic; chloride transport; signal transduction; gamma-aminobutyric acid signaling pathway; post-embryonic development
Research Articles on GABRG2
1. RNF34 regulates postsynaptic gamma2-GABAAR clustering and GABAergic synaptic innervation by interacting with and ubiquitinating the gamma2-GABAAR subunit promoting GABAAR degradation
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
